Loading
Life sciences · Journal article
Clinical Cancer Research · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Purpose: Selective RET inhibitors (SRIs) are the first-line standard for RET fusion-positive NSCLC, but no treatment is established after progression. Real-world outcomes are needed to inform trial design and contextualize single-arm studies in this rare population. Experimental design: Using the international RET-MAP registry (52 centers), we evaluated second-line platinum-pemetrexed with or without immunotherapy after first-line SRI progression and characterized third-line treatments after exposure to both regimens in any order. Results: Among 207 patients treated with first-line SRI, 81 (39%) discontinued because of progression; 65 (80%) received subsequent therapy, most commonly platinum-pemetrexed with or without immunotherapy (n=35, 54%). At 53 months' median follow-up, real-world objective response rate was 41% (12/29), median real-world progression-free survival (rwPFS) 6.1 months (95% CI 4.8-11.4), and median overall survival (OS) 13.7 months (95% CI 8.7-26.5). Outcomes were similar with chemotherapy alone (n=12) versus chemo-immunotherapy (n=23) for rwPFS (5.9 vs 6.8 months; HR 1.05, p=0.903) and OS (18.5 vs 13.7 months; HR 0.83, p=0.674). Three patients had rwPFS beyond 24 months with chemo-immunotherapy, all after short first-line SRI exposure. Among 32 patients receiving third-line therapy, taxane with or without antiangiogenic therapy was most common (n=11), with no responses and median rwPFS of 1.5 months (95% CI 0.8-NR). Conclusions: Second-line platinum-pemetrexed with or without immunotherapy achieved a median rwPFS of 6.1 months. Third-line outcomes were poor, highlighting the need for new treatment strategies.